Every Form 4 that Janux Therapeutics, Inc. (JANX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow JANX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JANX filings page.
Janux Therapeutics, Inc. director and President and CEO David Alan Campbell reported a bona fide gift of 123840.0000 shares of Common Stock on July 31, 2026. The transfer was recorded at $0.0000 per share, and he now directly holds 264742.0000 shares following the transaction.
Janux Therapeutics, Inc. President and CEO David Alan Campbell exercised stock options to acquire 7,000 shares of common stock at an exercise price of $4.21 per share. Following the transaction on July 8, 2026, he holds 388,582 common shares directly and 697,550 stock options remaining, with the exercised option series immediately exercisable and expiring on March 9, 2031.
Janux Therapeutics, Inc. reported insider-related equity awards linked to RA Capital–associated entities. An arrangement for Dr. Jake Simson includes a grant of 5,500 restricted stock units (RSUs), each representing one share of common stock, and 15,500 stock options with a $13.66 exercise price. The RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to Dr. Simson’s continuous service, while the options vest in equal monthly installments over the 12 months following June 11, 2026 and in any case by the next annual meeting. Dr. Simson holds these awards for the benefit of RA Capital funds, must deliver any net shares or cash to the adviser to offset advisory fees, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
Janux Therapeutics director Jake Simson reported equity awards tied to his board service. He received 5,500 restricted stock units, each representing one share of common stock, vesting on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continuous service. He was also granted options for 15,500 shares at an exercise price of $13.66 per share, vesting in equal monthly installments over the 12 months following June 11, 2026 and fully vested by the next annual meeting, subject to continued service. After these awards, his reported direct common stock holdings total 11,750 shares. Under an arrangement with RA Capital Management, these RSUs and options are held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., and Simson is obligated to turn over any net stock or cash received, so he disclaims beneficial ownership.
Janux Therapeutics director Winston Kung received new equity awards. He was granted 5,500 restricted stock units, each representing one share of common stock, and 15,500 stock options with an exercise price of $13.66 per share.
The RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continuous service. The options vest in equal monthly installments over the 12 months following June 11, 2026, and will in any case be fully vested by the next annual meeting, also subject to continued service. After the grant, Kung directly holds 11,750 shares of common stock.
Janux Therapeutics, Inc. director Natasha Hernday received new equity compensation awards. She was granted 5,500 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to her continuous service.
She was also granted a stock option for 15,500 shares of common stock at an exercise price of $13.66 per share, vesting in equal monthly installments over the 12 months following June 11, 2026 and fully vesting no later than the next annual stockholder meeting, contingent on continued service. Following these grants, she directly holds 15,481 shares of common stock.
Janux Therapeutics director Eric Dobmeier received new equity awards. He was granted 5,500 restricted stock units, each representing one share of common stock, which will vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continued service.
He was also granted options to buy 15,500 shares of common stock at an exercise price of $13.66 per share, expiring on June 10, 2036. These options vest in equal monthly installments over the 12 months following June 11, 2026 and will in any case be fully vested by the next annual stockholder meeting, subject to continued service. Following these grants, he directly holds 15,481 common shares.
Janux Therapeutics director Vickie L. Capps received new equity awards. She was granted 5,500 restricted stock units, each convertible into one share of common stock, increasing her direct holdings to 79,598 shares. She also received options on 15,500 shares at an exercise price of $13.66 per share, vesting over 12 months and fully by the next annual stockholder meeting, subject to continued service.
Janux Therapeutics director Ronald W. Barrett received new equity awards. He was granted 5,500 restricted stock units, each representing one share of common stock, increasing his direct common stock holdings to 11,750 shares. He also received a stock option for 15,500 shares at an exercise price of $13.66 per share, expiring on June 10, 2036.
The RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to his continuous service. The option vests in equal monthly installments over the 12 months following June 11, 2026, and will in any case be fully vested by the next annual stockholder meeting, also contingent on continued service.
Janux Therapeutics, Inc. reported that Chief Corp. & Business Development Officer Janeen Noel Doyle disposed of 4,059 shares of common stock on June 2, 2026 at a weighted average price of $14.029 per share. According to the footnotes, these shares were automatically sold to cover tax withholding obligations tied to the vesting of restricted stock units, indicating a routine, non-discretionary transaction rather than an active portfolio decision. Following this sale, Doyle directly holds 75,941 shares of Janux Therapeutics common stock.
Janux Therapeutics Vice President of Accounting Maria Dobek reported an open-market sale of 2,038 shares of Janux Therapeutics common stock at $14.17 per share on May 11, 2026. After this transaction, she continues to hold 32,270 shares directly.
Janux Therapeutics, Inc. reported an equity compensation grant to its Chief Medical Officer, William Go. On February 2, 2026, he received 44,000 shares of common stock in the form of restricted stock units that vest in four equal annual installments beginning February 1, 2027.
He was also granted a stock option for 154,000 shares of common stock at an exercise price of $13.99 per share. Twenty-five percent of this option vests on February 26, 2027, with the remaining shares vesting in equal monthly installments over the following three years. Both holdings are reported as directly owned.
Janux Therapeutics (JANX) reported an insider equity transaction by its Chief Business Officer. On 11/14/2025, the officer exercised a stock option for 3,333 shares of common stock at $10.59 per share and on the same date sold 3,333 shares at $30 per share. After these transactions, the officer beneficially owned 84,974 shares of Janux common stock directly and 118,101 stock options. The sale was conducted under a Rule 10b5-1 trading plan adopted on 09/30/2024. The filing also notes prior acquisitions of 1 share on 11/15/2024 and 2,834 shares on 05/15/2025 through the company’s 2021 Employee Stock Purchase Plan.
Janux Therapeutics (JANX) Form 4: The company’s Chief Business Officer reported two option exercises and a subsequent sale on 10/28/2025. He exercised 9,999 options at $4.21 and 6,666 options at $10.59, then sold 16,665 shares.
The sale’s weighted average price was $30.0622, with trades between $30.00 and $30.49, executed under a Rule 10b5-1 trading plan adopted on September 30, 2024. Following these transactions, he directly beneficially owned 82,139 shares.